SEER data show that small cell lung cancer (SCLS) incidence has steadily declined due to reduced smoking rates, but survival outcomes have seen only minimal improvement, underscoring the need for more ...

近年来，全球肿瘤研究与诊疗领域仿若被按下了“加速键”，呈现出一派蓬勃发展之势，为无数患者带来新的希望曙光。

The European Commission on Feb. 5 cleared Shanghai Henlius Biotech Inc.’s serplulimab (HLX-02) under the brand name of Hetronifly as a first-line combination therapy with carboplatin and etoposide to ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Results of 3 trials revealed that omitting transplant did not impact progression or survival outcomes for pediatric, ...

Unlike conventional high-dose chemotherapy regimens, MC uses low-dose agents like cyclophosphamide and etoposide, often in combination with non-chemotherapeutic agents such as celecoxib and ...

AstraZeneca has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for ...

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate around your body in the bloodstream. You might have chemotherapy if you have a higher risk of your cancer ...